Mc Clarren Financial Advisors, Inc. Nektar Therapeutics Transaction History

Mc Clarren Financial Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	BUY	$3.04 - $5.14 $477 - $806	157 New	157 $0
Q2 2022 Aug 11, 2022	SELL	$3.17 - $6.17 $497 - $968	-157 Closed	0 $0
Q3 2021 Oct 15, 2021	SELL	$13.07 - $18.84 $4,313 - $6,217	-330 Reduced 67.76%	157 $2,000
Q2 2021 Jul 23, 2021	BUY	$16.52 - $20.4 $5,451 - $6,731	330 Added 210.19%	487 $8,000
Q4 2020 Jan 29, 2021	BUY	$15.77 - $19.03 $2,475 - $2,987	157 New	157 $2,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Mc Clarren Financial Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Mc Clarren Financial Advisors, Inc. with notifications on news.